[HTML][HTML] Mechanistic support for combined MET and AR blockade in castration-resistant prostate cancer
A recent phase III trial of the MET kinase inhibitor cabozantinib in men with castration-
resistant prostate cancer (CRPC) failed to meet its primary survival end point; however, most …
resistant prostate cancer (CRPC) failed to meet its primary survival end point; however, most …
[PDF][PDF] Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer
ET Keller, GS Palapattu, AS Alva, DC Smith… - Neoplasia, 2016 - core.ac.uk
A recent phase III trial of the MET kinase inhibitor cabozantinib in men with castration-
resistant prostate cancer (CRPC) failed to meet its primary survival end point; however, most …
resistant prostate cancer (CRPC) failed to meet its primary survival end point; however, most …
[引用][C] Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer
Y Qiao, FY Feng, Y Wang, X Cao, S Han… - Neoplasia, 2016 - cir.nii.ac.jp
Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer
Y Qiao, FY Feng, Y Wang, X Cao… - … (New York, NY), 2016 - pubmed.ncbi.nlm.nih.gov
A recent phase III trial of the MET kinase inhibitor cabozantinib in men with castration-
resistant prostate cancer (CRPC) failed to meet its primary survival end point; however, most …
resistant prostate cancer (CRPC) failed to meet its primary survival end point; however, most …
[PDF][PDF] Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer
ET Keller, GS Palapattu, AS Alva, DC Smith… - …, 2016 - researchgate.net
A recent phase III trial of the MET kinase inhibitor cabozantinib in men with castration-
resistant prostate cancer (CRPC) failed to meet its primary survival end point; however, most …
resistant prostate cancer (CRPC) failed to meet its primary survival end point; however, most …
[PDF][PDF] Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer
ET Keller, GS Palapattu, AS Alva, DC Smith… - …, 2016 - cyberleninka.org
A recent phase III trial of the MET kinase inhibitor cabozantinib in men with castration-
resistant prostate cancer (CRPC) failed to meet its primary survival end point; however, most …
resistant prostate cancer (CRPC) failed to meet its primary survival end point; however, most …
[HTML][HTML] Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer
Y Qiao, FY Feng, Y Wang, X Cao, S Han… - … (New York, NY), 2016 - ncbi.nlm.nih.gov
A recent phase III trial of the MET kinase inhibitor cabozantinib in men with castration-
resistant prostate cancer (CRPC) failed to meet its primary survival end point; however, most …
resistant prostate cancer (CRPC) failed to meet its primary survival end point; however, most …
Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer
Y Qiao, FY Feng, Y Wang, X Cao… - Neoplasia …, 2016 - mdanderson.elsevierpure.com
A recent phase III trial of the MET kinase inhibitor cabozantinib in men with castration-
resistant prostate cancer (CRPC) failed to meet its primary survival end point; however, most …
resistant prostate cancer (CRPC) failed to meet its primary survival end point; however, most …
Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer.
Y Qiao, FY Feng, Y Wang, X Cao, S Han… - Neoplasia (New York …, 2016 - europepmc.org
A recent phase III trial of the MET kinase inhibitor cabozantinib in men with castration-
resistant prostate cancer (CRPC) failed to meet its primary survival end point; however, most …
resistant prostate cancer (CRPC) failed to meet its primary survival end point; however, most …